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Significance of this study
What is already known about this subject?
 ► The variability of insulin absorption increases over 
infusion set wear time and it may be attributed to the 
inflammatory tissue response.
What are the new findings?
 ► As the inflammatory tissue response progresses 
over infusion set wear time, the bolus volume and 
bolus surface area decrease, and this effect is di-
minished using angled insulin infusion catheters 
instead of straight infusion sets.
How might these results change the focus of 
research or clinical practice?
 ► The angle of insertion needs to be considered in 
future insulin infusion set design and clinical trials.
AbStrAct
Objective This study investigated the effects of the 
inflammatory tissue response (ITR) to an insulin infusion 
set (IIS) on insulin bolus spread over wear time, as well 
as the effect of cannula insertion angle on the ITR, bolus 
shape, and pump tubing pressure.
Research design and methods Angled or straight 
IISs were inserted every other day for 14 days into 
the subcutaneous tissue of 11 swine and insulin was 
delivered continuously. Prior to euthanasia, a 70 µL bolus 
of insulin/X- ray contrast agent was infused while recording 
a pressure profile (peak tubing pressure, pmax; area under 
the pressure curve, AUC), followed by the excision of 
the tissue- catheter specimen. Bolus surface area (SA) 
and volume (V) were assessed via micro- CT. Tissue was 
stained to analyze total area of inflammation (TAI) and 
inflammatory layer thickness (ILT) surrounding the cannula.
Results A bolus delivered through an angled IIS had 
a larger mean SA than a bolus delivered through a 
straight cannula (314.0±84.2 mm2 vs 229.0±99.7 mm2, 
p<0.001) and a larger volume (198.7±66.9 mm3 vs 
145.0±65.9 mm3, p=0.001). Both decreased significantly 
over wear time, independent of angle. There was a 
significant difference in TAI (angled, 9.1±4.0 mm2 vs 
straight, 14.3±8.6 mm2, p<0.001) and ILT (angled, 
0.7±0.4 vs straight, 1.2±0.7 mm, p<0.001). pmax (p=0.005) 
and AUC (p=0.014) were lower using angled IIS. As ILT 
increased, pmax increased, while SA and V decreased.
Conclusions The progression of the ITR directly affected 
bolus shape and tubing pressure. Although straight 
insertion is clinically preferred, our data suggest that 
an angled IIS elicits lower grades of ITR and delivers a 
bolus with lower tubing pressure and greater SA and V. 
The subcutaneous environment plays a crucial role in IIS 
longevity, and the insertion angle needs to be considered in 
future IIS designs and clinical trials.
InTROduCTIOn
The number of patients with type 1 and 
type 2 diabetes worldwide using continuous 
subcutaneous insulin infusion (CSII) therapy 
to manage their blood glucose (BG) levels 
is rising.1 Closed- loop and hybrid closed- 
loop automated insulin delivery systems 
have become accessible and show promising 
results by improving BG control, decreasing 
the incidence of hypoglycemia, and allevi-
ating some of the burden of the disease.2–4 
The weak link in the success of insulin pump 
therapy and artificial pancreas systems is still 
the insulin infusion set (IIS), in particular the 
cannula residing in the subcutaneous tissue 
of the patient. Manufacturers, regulators, and 
professional societies currently recommend 
changing a commercial Teflon IIS every 2–3 
days due to an increase in insulin absorp-
tion variability and therefore worsening 
of glycemic control.5 6 An ideal IIS would 
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produce rapid and consistent absorption of insulin from 
the subcutaneous tissue into the bloodstream from dose- 
to- dose and day- to- day for more than 7 days, and mini-
mize the formation of scar tissue that may adversely affect 
insulin absorption and future pump use.
It is debated whether a clinical difference exists 
between CSII catheters inserted at 90° compared with 
angled insertions (typically 30°–45°).7 8 A 90° (straight) 
IIS is generally preferred by patients due to its easier 
method of insertion, especially when teaching children 
or patients with poor dexterity.8 9 However, especially in 
slim patients, the risk of intramuscular injection is greater 
when inserting at 90°, which increases the incidence of 
cannula kinking, occlusion, insertion pain and hypo-
glycemia.7 10 It has been reported that using angled IIS 
reduces the risk of cannula kinking and dislodgment.8 9 11 
Although an increasing number of patients use Teflon 
IIS every day, there is a lack of systematic in vivo studies 
on the impact of angle of insertion on the subcutaneous 
inflammatory tissue response and the pattern of insulin 
delivery over time.
We have previously reported that the inflammatory 
response to the cannula of an IIS and insulin/preserva-
tives can have a significant effect on insulin absorption 
(pharmacokinetics).12 In the present study, we combined 
micro- CT imaging, histopathology and insulin tubing 
pressure analysis to investigate the progression of the 
inflammatory tissue response to straight and angled CSII 
catheters over time in a non- diabetic swine model. This 
animal model has been successfully used in prior studies 
by our group and collaborators,12 13 and has been shown 
to be the most adequate for human skin and adipose 
tissue wound healing.14 We hypothesized that the change 
in thickness of the layer of acute and chronic inflamma-
tory tissue surrounding the cannula of a CSII catheter 
has a direct effect on insulin spread (bolus volume and 
surface area) and tubing pressure. We further hypothe-
sized that the angle of insertion (90° vs 30°) would signifi-
cantly affect the total area of inflammation, the thickness 
of the inflammatory layer surrounding the cannula, the 
bolus surface area, bolus volume, and pump tubing pres-
sure during an insulin bolus.
ReseaRCH desIgn and meTHOds
Eleven healthy Yorkshire female swine, aged 3–6 months 
and weighing 60–70 kg, were used as a model of human 
subcutaneous tissue.14 15 Female swine were chosen over 
male animals due to their larger abdominal surface area. 
Swine were housed in a gated pen in groups of three for 
1 week of acclimation, and then separated by gated walls 
(ensuring snout contact) during the following 2 weeks of 
the study. All medications are listed in online supplemen-
tary table S1.
CsII catheter insertion
Animal studies took place over a period of 2–3 weeks 
(1 week of acclimation week followed by 2 study weeks 
with two to three animals studied in tandem). After 
placing the animals under general anesthesia using isoflu-
rane, commercially available CSII catheters with Teflon 
cannulas were inserted into the subcutaneous tissue of 
the shaved abdomen every other day for 14 days using 
aseptic technique (online supplementary figures S1 and 
S2). Sterile benzoin was applied to the skin surface to 
enhance adhesion of the CSII catheter adhesive, sparing 
the insertion site. Sufficient space was left between cath-
eters to ensure proper excision without overlap. Both 
angled and straight Teflon catheters were inserted using 
the spring- loaded automated inserter. Five swine had CSII 
catheters inserted at a 90° angle (Inset, Animas Corpora-
tion, West Chester, Pennsylvania, or Quickset Medtronic 
MiniMed, Northridge, California; 6 mm cannula length) 
and six swine at a 30° angle (Inset 30 Animas Corpora-
tion or Silhouette Paradigm Medtronic MiniMed; 13 mm 
cannula length). Sterile Tegaderm adhesive bandages 
were placed over the CSII catheters and infusion tubing 
to secure attachment to the skin and protect from mois-
ture/humidity during wear time. Therapeutic athletic 
kinesiology tape (KT Health, Vilnius, Lithuania) was used 
to cover the abdomen and provide additional protection 
against catheter dislodgment due to the movement of the 
animals.
Insulin infusion and Bg monitoring
Each catheter was connected to an insulin pump 
(OneTouch Ping, Animas Corporation or Paradigm 
REAL- Time Revel, Medtronic MiniMed) stored within 
a custom protective vest (Lomir Biomedical, Notre- 
Dame- de- l’Ile- Perrot, Quebec, Canada; online supple-
mentary figure S2). A basal infusion of dilute Lispro/
Humulog insulin (Eli Lilly, Indianapolis, Indiana) was 
continuously delivered throughout the duration of the 
study at a concentration of 5 units/mL (U-5) at a rate of 
0.05 units/hour. A 7- unit (70 µL) bolus was infused over 
45 s before each meal to mimic the everyday use of the 
pump therapy. Insulin Lispro was diluted per manufac-
turer’s recommendation with a sterile diluent (Eli Lilly). 
BG levels were monitored with intermittent capillary BG 
measurements using a commercial glucose meter and 
test strips (Bayer Contour Next, Parsippany, New Jersey).
Tubing pressure recording
On the final day of the study, swine were placed under 
general endotracheal anesthesia and a final 70 µL bolus 
of dilute insulin and X- ray contrast agent (70% U-100 
Lispro, 30% IsoVue 300) was infused. A pressure sensor 
(PendoTECH, Princeton, New Jersey) was intercon-
nected between the IIS and the pump, and connected to 
a data logger (MSR Electronics, Switzerland). A custom 
amplifier supplied by Capillary Biomedical was perma-
nently attached to the pressure sensor (online supple-
mentary figure S3). Pressure data were standardized to a 
baseline of 5 s and a maximum time of 300 s (5 min). The 
peak pressure (pmax) and area under the curve (AUC) 
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were determined for each bolus data set. AUC measure-
ments were calculated using the trapezoidal method.
Tissue excision and imaging
After 5 min of pressure recording, CSII catheters and 
surrounding tissue were excised and specimens gently 
frozen in isopentane cooled with dry ice (Iso- CO2) for 
subsequent micro- CT imaging. Following removal of the 
CSII catheter- tissue specimens, each swine was eutha-
nized by intravenous injection of Beuthanasia (1 mL/4.5 
kg body weight) solution while under general anesthesia.
After excision, frozen CSII catheter- tissue specimens 
were imaged using a micro- CT scanner (Inveon, Siemens 
Medical Solutions USA, Knoxville, Tennessee) to deter-
mine the three- dimensional (3D) distribution pattern 
of insulin/X- ray contrast agent in the subcutaneous 
tissue. The surface area and volume of the insulin/
contrast agent bolus infused into the subcutaneous tissue 
were measured using 3D visualization imaging software 
(Amira, Thermo Fisher Scientific, Hillsboro, Oregon). 
The excised tissue was then fixed, grossed, sectioned, 
and stained with H&E and Masson’s trichrome stain. The 
area of inflammation (Rasband, WS, ImageJ, US National 
Institutes of Health, Bethesda, Maryland, 1997–2018; 
https:// imagej. nih. gov/ ij/) and the thickness of the 
inflammatory layer (Leica Biosystems, Buffalo Grove, 
Illinois) were measured on all catheters with ≥35% view 
of the channel (online supplementary figures S4 and 
S5). The percentage of the catheter channel shown was 
determined by measuring the length of the void length 
and dividing it by the length of the catheter (90°=6 mm; 
30°=13 mm).
statistical analysis
Micro- CT, tissue histology, and tubing pressure data were 
analyzed using analysis of variance with generalized linear 
model. Kruskal- Wallis test was used for data not normally 
distributed and post- hoc analyses were performed with 
Bonferroni correction. Pearson correlation and linear 
regression analysis were used to examine relationships 
between variables of interest. A p<0.05 was set for statis-
tical significance. Statistical analyses were performed with 
SYSTAT V.13.0 and GraphPad Prism V.5.0 (GraphPad 
Software, San Diego, California).
ResulTs
The methods described above were successfully carried 
out in 11 swine with no adverse events or symptomatic 
hypoglycemia. We inserted a total of 48 angled and 40 
straight catheters. One straight and two angled IIS were 
accidentally removed and thus excluded from analysis. 
Two IIS produced a pump occlusion alarm (90° inserted 
for 4 days and 30° inserted for 2 days) when delivering a 
bolus of insulin/X- ray contrast agent.
Tissue histology images
A total of 66 catheters were included in the analysis of 
tissue histology (online supplementary tables S3 and S4). 
Samples were included if the histology image showed at 
least 35% of the cannula channel. The mean channel view 
was 70.6% for angled and 90.1% for straight cannulas 
(p<0.001).
In general, the total area of inflammation increased 
consistently from day 0 to day 8 around both CSII cannula 
types, then remained relatively stable from day 8 to day 
14 (figure 1A). On average, the total area of inflamma-
tion was significantly larger around Teflon cannulas 
inserted at 90° compared with those inserted at 30° 
(p<0.001; table 1). Inflammation area was significantly 
larger around 90° cannula compared with 30° cannula 
on days 8–14 postinsertion (p<0.05; figure 1A).
A thick layer of inflammatory tissue (approximately 
900 µm) already developed around the 90° straight 
cannula after 2 days of wear time. The layer of inflamma-
tory tissue around the 30° angled cannula was significantly 
thinner after 2 days of wear time than the 90°cannula 
(figure 1B; p=0.005 vs 30°). The layer of inflammatory 
tissue around each Teflon cannula varied in composition, 
thickness, and continuity. Inflammatory layer thickness 
around the 90° cannula consistently increased from day 
0 to day 10, and then stabilized through day 14. Inflam-
matory layer thickness around the 30° cannula increased 
from day 0 to day 4, and then stabilized through day 14 
(figure 1B). The layer of inflammatory tissue around the 
30°cannula was significantly thinner on day 8 through 
day 14 of wear time, compared with the 90° cannula. 
Layer thickness around the 90° cannula was consistently 
thicker compared with the 30° cannula over 2 weeks of 
wear time (p<0.001; figure 1B and table 1).
micro-CT images
Seventy- six catheters were included for micro- CT image 
analysis (online supplementary table S2). Catheters were 
excluded if a pump alarm occlusion occurred (n=2) or no 
contrast was detected in the tissue (n=1). While studying 
the first animal, micro- CT methods were developed for 
all subsequent studies and thus all eight CSII catheters 
from this animal were not included in the analysis.
The 70 µL bolus of insulin and X- ray contrast agent 
mixed with the tissue fluid adjacent to the cannula, greatly 
increasing the measured volume and surface area of the 
bolus within the tissue. The average volume of a bolus of 
insulin/X- ray contrast agent in the subcutaneous tissue 
was three times larger than the infused 70 µL. Contrast 
agent density was highest adjacent to the cannula orifice 
and lowest in the tissue several millimeters away from the 
orifice.
Although the pump was always set to deliver 7 units, in 
four instances (5%) of all included IIS, less than 70 µL was 
detected within the tissue (1× angled, 3× straight) without 
an occlusion alarm. In one instance (straight, catheter 
excluded from analysis), no contrast agent entered the 
tissue, again without a pump occlusion alarm. Indepen-
dent of wear time, a bolus of insulin/X- ray contrast agent 
delivered through catheters inserted at 30° had a signifi-
cantly larger mean surface area (p<0.0001) and volume 
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Figure 1 Histopathology. (A) Area of inflammation and (B) thickness of inflammatory layer around the cannulas of CSII 
catheters inserted at 30° and 90° over wear time. Values are shown as mean±SD, n=76 catheters in each group; *p<0.05 
vs 30°, ANOVA- GLM. Micro- CT. (C) Bolus surface area and (D) bolus volume over catheter wear time. Values are shown as 
mean±SD, n=66; *p<0.05 vs 90°, +p<0.05 vs day of insertion, ANOVA- GLM with Bonferroni correction (micro- CT image for day 
0, angled CSII catheter not available). (E) Panel of representative images of tissue histology and micro- CT images of catheter- 
tissue specimens for each day. Contrast agent spread in the tissue is shown in orange, and CSII catheter hub on skin surface in 
teal. Trichrome stains of representative histology slides show the layer of inflammatory tissue over time around the void (white) 
left by the cannula after removal. Fibrin and red blood cells are stained red; collagen/connective tissue is stained light or dark 
blue. Blue and orange scale bars are equivalent to 3 mm. ANOVA- GLM, analysis of variance- generalized linear model; CSII, 
continuous subcutaneous insulin infusion.
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Figure 2 Pressure analysis. (A) Changes in maximum tubing pressure over wear time. (B) Changes in area under the pressure 
curve over wear time. Values are shown as mean±SEM.
Table 1 Summary of data averaged over all days
Surface area 
(mm2) P value Volume (mm3) P value SA:V (mm-1) P value
Micro- CT 30° 314.0+84.2 <0.0001 198.7+66.9 0.001 1.7±0.4 1.0
90° 229.0+99.7 145.0+65.9 1.7±1.5
Total area of inflammation
(mm2) P value
Thickness of layer of 
inflammation (mm) P value
Histology 30° 9.1±4.0 <0.001 0.7±0.4 <0.001
90° 14.3±8.6 1.2±0.7
Median pmax (mm Hg/kPa) P value Median AUC (mm Hg/s) P value
Tubing pressure 30° 1176.9±828.4 0.005 30 672.7±62 322.1 0.01
90° 2113.5±861.9 60 938.5±176 089.0
Micro- CT (n=76) and histology (n=66) values are shown as mean±SD. Tubing pressure (n=66) values are shown as median±SD.
AUC, area under the curve; pmax, peak pressure; SA:V, surface area to volume ratio.
(p=0.001) than those delivered through a 90° catheter 
(table 1). There was no difference between angled and 
straight CSII catheters in bolus surface area to volume 
ratio.
The surface area and volume of insulin/X- ray contrast 
bolus delivered into the subcutaneous tissue around both 
types of CSII catheters generally decreased for several 
days after insertion, then stabilized (figure 1C,D). Of 
clinical interest, the surface area of the bolus delivered 
through the 90° straight cannula into the subcutaneous 
tissue was significantly smaller than the surface area deliv-
ered through the 30° angled cannula on day 2 and day 4 
of wear time (figure 1C; p<0.05). The volume of a bolus 
delivered through a straight cannula into the subcuta-
neous tissue was significantly smaller than the volume 
delivered through an angled cannula on day 2 of wear 
time (figure 1D; p<0.05). A bolus delivered through a 90° 
straight cannula had a significantly smaller surface area 
on days 2, 4, 10, 12, and 14 compared with the day of 
insertion (figure 1C; p<0.05). The surface area of a bolus 
delivered through an angled cannula was not significantly 
different on all days of wear time compared with day 1, 
except significantly decreased on day 4 (figure 1C). In 
general, the bolus volume was higher on the day of inser-
tion (day 0) compared with all days postinsertion when 
infused through both types of CSII catheters (figure 1D). 
This difference in bolus volume was statistically significant 
on day 4 (90°) and day 8 (30°) versus day 1. Measured 
volume was on average three times the infused volume 
of 70 µL. For both catheter types, the volume and surface 
area of a bolus decreased over 4 days before leveling out 
at values >70 µL (figure 1D).
Twenty- four of the angled cannulas were observed to 
kink (52%) within the subcutaneous tissue by micro- CT 
imaging, and 13 of the straight cannulas (43%). Kinks 
most commonly occurred immediately below the dermis 
or just proximal to the cannula tip.
Tubing pressure
The maximum tubing pressure (pmax) as well as the area 
under the pressure curve (AUC) measured over 5 min 
were significantly higher for straight CSII catheters when 
infusing a bolus of 70 µL (table 1). Independent of wear 
time the median pmax was 44% lower in angled infusion 
sets compared with straight CSII catheters (p=0.005), 
while the median AUC was reduced by 50% (p=0.01). 
The AUC was especially high on days 0, 2, and 4 for 
straight IIS and dropped to values similar to angled IIS 
after 6 days of wear time (n.s.; figure 2). It is important 
to note that the SDs of pmax and AUC were quite large, as 
we did not exclude extreme values from pump occlusion 
alarms or leaks onto the skin (figure 2).
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Figure 3 Correlations. (A) Layer of inflammation versus bolus volume. (B) Layer of inflammation versus bolus surface area. (C) 
Layer of inflammation versus peak tubing pressure. (D) Bolus surface area versus peak tubing pressure. *p<0.05, **p<0.005
Correlations
To better understand potential relationships among the 
variables described above, we performed correlations 
between the micro- CT, histology, and pressure analysis. 
We found that as the thickness of the inflammatory 
layer increased, the volume (p<0.05) and surface area 
(p<0.005) of a bolus decreased, while pmax increased 
(p<0.05; figure 3A–C). Additionally, as pmax increased, the 
bolus surface area decreased (figure 3D).
dIsCussIOn
Our findings suggest that catheters inserted at a 30° 
angle elicit a significantly lower inflammatory response 
compared with catheters inserted at 90°. The 30° inser-
tion angle also resulted in a greater volume and surface 
area (spread) of an insulin bolus, and was associated 
with lower tubing pressures compared with straight IIS. 
The novelty of this work stems from the combination of 
pressure analysis, micro- CT imaging, and histopathology, 
giving greater insight into the mechanisms of insulin 
absorption variability and other CSII therapy failure 
modes.
The acute inflammatory response following CSII 
cannula insertion is triggered by the initial trauma of 
piercing the epidermis, dermis, and subcutaneous tissue 
with a steel introducer needle and Teflon cannula.16 17 
Consequently, insulin is delivered into an area of damaged 
cells, connective tissue and extracellular matrix, charac-
terized by a loss of functional capillary and lymphatic 
vessels.16 Over wear time, neutrophils, macrophages, and 
fibroblasts infiltrate the region to form a layer of acute and 
chronic inflammatory tissue around the Teflon cannula 
containing proteolytic enzymes.16 The accumulation of 
inflammatory cells, thrombus, and fresh collagen (desig-
nated layer of inflammation) requires insulin to travel the 
path of least resistance toward intact and functional capil-
laries and lymph vessels.12 18 A surrounding layer that is 
thick, dense, and continuous will significantly hinder 
the dispersion and diffusion of insulin molecules to 
the surface of functional capillary and lymph vessels for 
absorption into the circulation. Insulin may be degraded 
within the wound or travel upward onto the skin surface 
along the path of least resistance, due to a non- compliant 
continuous layer of inflammatory tissue surrounding the 
cannula. This concept of variable flow resistance due to 
a mechanical barrier may explain the high variability 
in bolus shape patterns over wear time observed in this 
study (figure 1E). Our results show that with increasing 
thickness of the inflammatory layer, the volume and 
surface area of an insulin bolus in the subcutaneous 
tissue decrease and insulin tubing pressure increases. 
This may suggest that insulin flow into the adjacent tissue 
is interrupted, possibly affecting glycemic control in a 
real- life setting.
Independent of the cannula angle, both the inflam-
matory layer thickness and the area of inflammation 
increased steadily over the first 4 days of wear time. 
Patients are instructed to change their IIS after 2–3 days 
to reduce the incident of skin irritation, poor glycemic 
control, and occlusion rates, all of which increase by 40% 
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by day 5.5 6 19 With increasing wear time, insulin absorp-
tion into the circulation becomes more variable and less 
reliable, resulting in an incidence of unexplained hyper-
glycemia of up to 68% in the first 72 hours after catheter 
insertion.8 20 21 Wearing the infusion set for 4 days instead 
of 2 days can increase the risk of hyperglycemia by almost 
40%.6
The decrease in compliant healthy tissue over wear 
time may explain the rise in tubing pressure (pmax, AUC), 
as insulin has increasing difficulty finding a path through 
the subcutaneous tissue. Tubing pressure was decreased 
by 50% using angled compared with straight CSII 
catheters, suggesting an easier flow of insulin into the 
surrounding tissue. Patients experience both occlusions 
triggering a pump alarm and the so- called ‘silent occlu-
sions’ in their clinical routine with a reported increase 
in occlusions after 3 days of IIS use.5 22 While we only 
registered two pump occlusion alarms, we saw 11 cases of 
elevated pressure profiles where tubing pressure did not 
return to baseline after bolus delivery but did not cause 
the pump to alarm (see online supplementary material 
II). In five of these instances without pump alarm, the 
delivered volume was much less than the expected 70 µL 
(between 0 and 50 µL). In a real- life setting, these types of 
events could worsen BG control and increase the risk for 
hypoglycemia and diabetic ketoacidosis (DKA).
We found a significant difference in tissue response 
and insulin bolus distribution using CSII catheters of 
different angles. There is limited literature on the number 
of patients using an angled IIS and/or the reasons for 
choosing it. Published literature on catheter angle of 
insertion draws conclusions mainly from patient testimo-
nies, case studies, and/or surveys, or does not differen-
tiate between angles but merely cannula material.10 11 23 24 
Heinemann and Krinelke25 reported in 2012 that only 
about 20%–30% of patients use angled Teflon CSII cath-
eters, while also prompting the question whether more 
studies on the angle of insertion should be conducted. A 
case study by Kuroda et al26 reported that patients using 
angled IIS experience less unexpected hyperglycemia 
and premature catheter failure. An angled CSII catheter 
is less likely to hit the muscle layer, which has two advan-
tages: first, the inflammatory response may be less severe, 
and second the incidence of cannula kinking and/or 
obstruction is decreased.7–9 Our results do not support 
the latter as we found that more angled cannulas kinked 
(52% vs 43%). This may be attributed to our method 
of measuring kinks through micro- CT analysis, rather 
than inspecting the cannula once it is already removed. 
In summary, our results showed that angled CSII cath-
eters were associated with a lower inflammatory tissue 
response and lower tubing pressures. Both bolus surface 
area and volume were significantly larger when infused 
through angled IIS, suggesting an increased contact of 
insulin with capillaries and lymph vessels.
While our findings were significant, there are limita-
tions to our methods and analysis. First, the histology 
images used for analysis were produced from a thin film 
of tissue (2–5 µm), thus only providing a snapshot of the 
inflammatory response to the cannula of a CSII catheter. 
Second, locating an angled insertion channel in a fatty 
tissue specimen is methodologically more challenging 
than for straight catheters. To account for this limitation, 
we only included images showing at least 35% of the 
insertion channel and created four standardized points 
to measure the thickness of layer of the inflammatory 
tissue, measured independently by two investigators. We 
expected the total area of inflammation to remain similar 
regardless of the channel view and found this to be true 
for a data subset (results not shown). Third, micro- CT 
imaging was performed on frozen tissue samples to 
preserve the shape of the bolus, but freezing the spec-
imen affects the structure of the subcutaneous tissue 
and may cause artifacts. Others, however, have success-
fully employed similar methods to analyze insulin bolus 
shape and distribution in the subcutaneous tissue.27 28 
In order to better understand how insulin distribution, 
inflammation and pressure influence insulin absorption, 
future studies should include insulin pharmacokinetic 
clamp experiments. The set- up presented here required 
large amounts of skin and subcutaneous tissue, ruling out 
a human study. Although the outcome may not be the 
same as in a patient with diabetes, swine skin and subcuta-
neous tissue are similar to human tissue in their structure 
and wound healing pattern.14 15
The CSII catheter is considered the weak link of insulin 
pump therapy, often failing to ensure reliable dose- to- 
dose or day- to- day insulin delivery/absorption, leading to 
clinical complications such as hypoglycemia and hyper-
glycemia or DKA.25 Our results show that even when the 
pump fails to deliver a full bolus into the subcutaneous 
tissue, it will sometimes fail to alarm, and the same holds 
true for unusually high tubing backpressures. Unreliable 
insulin delivery may cause clinical problems in the daily 
therapy of an insulin- dependent patient. We furthermore 
show that after approximately 6 days of wear time, the 
inflammatory tissue response to a Teflon cannula stabi-
lizes. This suggests that the wear time of a CSII cath-
eter may be prolonged by overcoming the initial acute 
inflammatory response and thus the associated variability 
in insulin absorption. To our knowledge, this is the first 
systematic study assessing tissue response, bolus distri-
bution and tubing pressure of commercially available 
angled and straight Teflon CSII catheters and the first 
to correlate these findings over CSII catheter wear time. 
Based on our findings, we believe that in future studies, 
CSII catheters should not only be grouped by mate-
rial but also separated by angle of insertion, in order 
to adequately drive future IIS recommendations. The 
methods and results presented here may assist in the 
design of future studies to develop an ideal IIS with reli-
able dose- to- dose and day- to- day delivery and absorption 
of insulin over an extended duration of wear time.
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